Harrow achieved record quarterly revenue of $89.1 million in Q4 2025, a 33% increase over the prior-year period. Full-year 2025 revenue reached $272.3 million, marking a 36% increase compared to 2024. GAAP net income for Q4 2025 was $6.6 million, while the full-year 2025 resulted in a net loss of $5.1 million. Adjusted EBITDA was $24.2 million in Q4 2025 and $61.9 million for the full-year 2025. The company generated $43.9 million in operating cash flow in 2025, a significant improvement from $(22.2) million used in operations in 2024. Cash and cash equivalents stood at $72.9 million as of December 31, 2025. VEVYE revenue grew to $25.9 million in Q4 2025 and $88.7 million for the full-year 2025, representing increases of 62% and 216% respectively. IHEEZO revenue increased to $35.9 million in Q4 2025 and $81.3 million for the full-year 2025, up 57% and 65% respectively. TRIESENCE recorded its highest quarterly revenue since relaunch at $5.1 million in Q4 2025. Harrow provided full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA guidance of $80 million to $100 million. Strategic initiatives for 2026 include doubling the VEVYE and TRIESENCE sales teams and expanding IHEEZO into office-based settings. The company expects to launch BYOOVIZ (LUCENTIS biosimilar) mid-year 2026 and OPUVIZ (EYLEA biosimilar) in January 2027. Compounded product revenue is projected to decline by approximately 10-20% in 2026 as the company shifts towards FDA-approved branded products.